Quadruple Pathway Therapy • Coming Soon
The Future of Multi-Pathway Weight Loss
This advanced investigational combination pairs Retatrutide (a triple GIP/GLP-1/Glucagon agonist) with Cagrilintide (a long-acting amylin analogue) to target four distinct metabolic pathways simultaneously. Neither compound is FDA approved; this represents the cutting edge of obesity research. Join our waitlist to be notified when available.
4
Receptor Pathways Targeted
24%+
Potential Weight Loss*
2x
Weekly Injections
TBD
Availability Timeline
Coming Soon
An advanced combination therapy pairing two investigational compounds for multi-pathway metabolic targeting. This formulation is not yet available and both compounds are pending FDA approval.
Retatrutide 10mg + Cagrilintide 2.5mg
Potential For
Patients seeking maximum multi-pathway support. This combination represents the frontier of metabolic pharmacotherapy, targeting more pathways than any single approved medication.
The Science
This investigational combination pairs two cutting-edge compounds: Retatrutide (a triple GIP/GLP-1/Glucagon receptor agonist) and Cagrilintide (a long-acting amylin analogue). Together, they target four distinct metabolic pathways—more than any single approved obesity medication.
Retatrutide’s triple action reduces appetite via GLP-1, enhances fat metabolism via GIP, and increases energy expenditure via glucagon. Cagrilintide adds amylin pathway activation, which promotes satiety through different brain mechanisms and further slows gastric emptying.
While CagriSema (cagrilintide + semaglutide) has shown 20-22% weight loss in Phase 3 trials, and retatrutide alone achieved 24.2% in Phase 2, researchers theorize that retatrutide + cagrilintide could potentially surpass both by combining four pathways instead of two or three.
Join the Waitlist
How It Works
By combining retatrutide with cagrilintide, this therapy targets four distinct hormone pathways for comprehensive metabolic support.
Enhances insulin sensitivity and fat metabolism. Works synergistically with GLP-1 to amplify metabolic effects.
Reduces appetite, slows gastric emptying, and promotes satiety—the proven mechanism behind effective weight loss.
Increases energy expenditure and promotes fat oxidation—a mechanism unique to retatrutide among GLP-1 therapies.
Cagrilintide adds satiety via brainstem pathways distinct from GLP-1, further slowing gastric emptying and food intake.
Pathway Comparison
Each generation of weight loss medication targets more metabolic pathways. This combination represents the most comprehensive approach in development.
*No clinical trial data exists for this specific combination. Theoretical potential based on individual compound mechanisms.
Theoretical Benefits
Four receptor targets (GIP, GLP-1, Glucagon, Amylin) may provide more comprehensive metabolic support than any single-agent or dual-agent therapy.
Cagrilintide’s amylin pathway works through different brain mechanisms than GLP-1, potentially enhancing satiety beyond what either compound achieves alone.
Retatrutide’s glucagon activation increases calorie burning—a mechanism absent from semaglutide, tirzepatide, and cagrilintide alone.
Both compounds slow gastric emptying through different pathways, potentially creating more sustained fullness after meals.
Where CagriSema combines amylin + GLP-1, this combination adds GIP and glucagon—two pathways shown to enhance weight loss in clinical trials.
Multiple pathway activation may offer benefits for blood sugar control, lipid profiles, and liver fat reduction beyond weight loss alone.
What to Do Now
Neither retatrutide nor cagrilintide are FDA approved, and this combination is highly investigational. Here’s how we can help you start your weight loss journey today.
Sign up to be notified about emerging therapies as they become available through FDA approval.
Discuss FDA-approved options with our physicians—semaglutide and tirzepatide are available now with proven results.
Begin your weight loss journey with current therapies while monitoring developments in multi-pathway research.
We’ll keep you updated as retatrutide, cagrilintide, and combination therapies progress through clinical trials.
Important Information
This combination therapy is highly investigational. Neither retatrutide nor cagrilintide have received FDA approval, and no clinical trials have studied this specific combination together.
4
Metabolic pathways targeted by this combination (GIP, GLP-1, Glucagon, Amylin)
TBD
No timeline for FDA approval of this combination therapy
Questions
No. Neither retatrutide nor cagrilintide are FDA approved, and no clinical trials have studied this specific combination. Both compounds are in Phase 3 trials independently. This page is for educational purposes about emerging research in multi-pathway weight loss therapy.
Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. Amylin is a hormone released by the pancreas that promotes satiety and slows gastric emptying. In Phase 3 trials (REDEFINE program), cagrilintide alone achieved 11.8% weight loss, and combined with semaglutide (CagriSema) achieved 20-22% weight loss.
The theoretical rationale is that retatrutide targets GIP, GLP-1, and glucagon receptors, while cagrilintide targets amylin receptors—a pathway not covered by retatrutide. Since CagriSema (cagrilintide + semaglutide) showed that adding amylin to GLP-1 improves results, researchers theorize that adding amylin to retatrutide’s triple action could provide even greater benefits.
Currently, there is no clinical trial data for retatrutide + cagrilintide specifically. The evidence is theoretical, based on the individual efficacy of each compound and the success of CagriSema (cagrilintide + semaglutide). Any claims about combined efficacy are speculative until clinical trials are conducted.
No. Neither compound is FDA approved for commercial sale. Be extremely cautious of any source claiming to sell retatrutide or cagrilintide outside of clinical trials—these products are unregulated and potentially dangerous. We offer FDA-approved options like semaglutide and tirzepatide today.
There is no timeline. Retatrutide and cagrilintide must each complete Phase 3 trials and receive FDA approval (expected 2026-2027 at earliest). Only then could combination therapy be studied. It could be several years before such a combination is commercially available, if ever.
Start with FDA-approved options available today. Semaglutide and tirzepatide have proven efficacy (15-22% weight loss) with established safety profiles. Our physicians can help you begin treatment now and discuss transitioning to newer therapies as they become available through proper FDA approval.
Stay Updated
Be the first to know about emerging multi-pathway therapies. In the meantime, our team can discuss FDA-approved options like semaglutide and tirzepatide available today.
"*" indicates required fields
Or call us directly: +1 213-325-3373
*IMPORTANT: This page describes an investigational combination of two compounds (retatrutide + cagrilintide) that are NOT FDA approved. No clinical trials have studied this specific combination. All efficacy claims are theoretical based on individual compound data. Retatrutide and cagrilintide are each in Phase 3 clinical trials and available only through trial participation. Any source claiming to sell these compounds outside of clinical trials is unregulated and potentially dangerous. BHRC does not currently offer either compound. This page is for educational purposes about emerging research in obesity pharmacotherapy. Consult with our medical team about FDA-approved weight loss options available today.
